021-51111890
购物车（）
sales@molnova.cn
WAY-200070
CAS No. 440122-66-7
WAY-200070 ( WAY200070;WAY 200070 )
产品货号. M14497 CAS No. 440122-66-7
WAY-200070 is a potent, highly selective ERβ agonist with IC50 of 3 nM, displays 68-fold selectivity over ERα (IC50=260 nM).
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥405 | 有现货 |
|
| 5MG | ￥648 | 有现货 |
|
| 10MG | ￥915 | 有现货 |
|
| 25MG | ￥1968 | 有现货 |
|
| 50MG | ￥3483 | 有现货 |
|
| 100MG | ￥5152 | 有现货 |
|
| 500MG | ￥11016 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称WAY-200070
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述WAY-200070 is a potent, highly selective ERβ agonist with IC50 of 3 nM, displays 68-fold selectivity over ERα (IC50=260 nM).
-
产品描述WAY-200070 is a potent, highly selective ERβ agonist with IC50 of 3 nM, displays 68-fold selectivity over ERα (IC50=260 nM); induces galanin expression within gonadotropin hormone-releasing hormone-immunoreactive neurons in the female rat brain, causes and learn the socially acquired preferenc in mice, deonstrates the anxiolytic-like and antidepressant-like effects in vivo.
-
同义词WAY200070;WAY 200070
-
通路Endocrinology/Hormones
-
靶点Estrogen Receptor/ERR
-
受体ERRα;ERRβ
-
研究领域Neurological Disease
-
适应症——
化学信息
-
CAS Number440122-66-7
-
分子量306.11
-
分子式C13H8BrNO3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 31 mg/mL
-
SMILESO=C1C=C/C(C=C1)=C2OC3=C(Br)C=C(O)C=C3N/2
-
化学全称5-Benzoxazolol, 7-bromo-2-(4-hydroxyphenyl)-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Hughes ZA, et al. Neuropharmacology. 2008 Jun;54(7):1136-42.
2. Clipperton AE, et al. Neuropsychopharmacology. 2008 Sep;33(10):2362-75.
3. Malamas MS, et al. J Med Chem. 2004 Oct 7;47(21):5021-40.
2. Clipperton AE, et al. Neuropsychopharmacology. 2008 Sep;33(10):2362-75.
3. Malamas MS, et al. J Med Chem. 2004 Oct 7;47(21):5021-40.
产品手册
关联产品
-
Nylestriol
Nylestriol is an agonist of estrogen receptor.
-
SAR439859
SAR439859 is an orally active, nonsteroidal and selective degrader of estrogen receptor (SERD).
-
Giredestrant
Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain.?Giredestrant has anti-tumor activity.
